Physician profile
Amanda Cardin
NPI 1609379783
$3,044.59
in general payments reported to CMS, 2019-2025
29 companies · $54.15 in 2025
The $54.15 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,412 · 2022: $1,579 · 2025: $54.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $54.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $54.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $685.34 | 2021-2022 | |
| Glaxosmithkline, LLC. | $516.08 | 2021-2022 | |
| Novo Nordisk INC | $433.56 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $150.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $149.75 | 2021 | |
| Amgen INC. | $140.35 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $105.26 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $97.98 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.44 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.54 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $57.04 | 2021-2022 | |
| Gilead Sciences, INC. | $54.15 | 2025 | Livdelzi |
| Amarin Pharma, INC. | $52.14 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.88 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $49.17 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $45.38 | 2021-2022 | |
| Lilly USA, LLC | $41.78 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $35.43 | 2022 | |
| Acadia Pharmaceuticals INC | $34.06 | 2021-2022 | |
| Pfizer INC. | $31.09 | 2021 | |
| Merck Sharp & Dohme LLC | $27.39 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $24.86 | 2021-2022 | |
| Biogen, INC. | $20.65 | 2022 | |
| Arbor Pharmaceuticals, INC. | $20.51 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.03 | 2021 | |
| Ucb, INC. | $15.96 | 2022 | |
| Vanda Pharmaceuticals INC. | $13.85 | 2022 | |
| Ironwood Pharmaceuticals, INC | $13.66 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Cardin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.